Krystal Biotech (NASDAQ:KRYS) Posts Earnings Results, Beats Expectations By $0.07 EPS

Krystal Biotech (NASDAQ:KRYS - Get Free Report) issued its earnings results on Monday. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.84 by $0.07, Briefing.com reports. Krystal Biotech had a return on equity of 1.99% and a net margin of 63.73%. The company had revenue of $83.84 million during the quarter, compared to the consensus estimate of $82.94 million. During the same period last year, the business posted ($0.67) EPS. The firm's revenue for the quarter was up 879.9% compared to the same quarter last year.

Krystal Biotech Stock Performance

KRYS traded up $3.56 during midday trading on Tuesday, reaching $174.41. The company had a trading volume of 245,166 shares, compared to its average volume of 329,234. The stock has a market cap of $5.01 billion, a PE ratio of 97.94 and a beta of 0.82. The business has a 50-day moving average price of $182.28 and a two-hundred day moving average price of $180.12. Krystal Biotech has a 12-month low of $93.95 and a 12-month high of $219.34.

Analyst Upgrades and Downgrades

KRYS has been the subject of a number of recent research reports. Evercore ISI boosted their price target on shares of Krystal Biotech from $201.00 to $206.00 and gave the company an "outperform" rating in a research note on Monday, August 12th. Cantor Fitzgerald restated an "overweight" rating on shares of Krystal Biotech in a report on Thursday, August 29th. Stifel Nicolaus boosted their price objective on Krystal Biotech from $204.00 to $220.00 and gave the stock a "buy" rating in a report on Wednesday, September 11th. Chardan Capital upped their price target on Krystal Biotech from $153.00 to $208.00 and gave the stock a "buy" rating in a report on Monday, August 5th. Finally, HC Wainwright reiterated a "buy" rating and issued a $221.00 target price on shares of Krystal Biotech in a research note on Tuesday. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Krystal Biotech currently has a consensus rating of "Buy" and an average target price of $197.00.

Insider Activity at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the completion of the transaction, the insider now owns 1,500,882 shares in the company, valued at approximately $296,814,424.32. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 14.10% of the stock is owned by company insiders.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).